Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Affimed NV

AFMD
Current price
0.45 USD -0.019 USD (-4.07%)
Last closed 0.45 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 67 202 552 USD
Yield for 12 month -78.57 %
Week
Month
Year
AFMD
21.11.2021 - 28.11.2021

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia. The company also develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. In addition, it has collaboration with Artiva Biotherapeutics to develop the combination of AFM13 with Artiva's AB-101 NK cell therapy; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and research collaboration and license agreement with Genentech for the development and commercialization of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. Address: Technologiepark, Heidelberg, Germany, 69120

Analytics

WallStreet Target Price

5.67 USD

P/E ratio

Dividend Yield

Current Year

+45 019 868 USD

Last Year

+43 945 349 USD

Current Quarter

+2 135 975 USD

Last Quarter

+1 513 255 USD

Current Year

+45 019 868 USD

Last Year

+43 945 349 USD

Current Quarter

+2 135 975 USD

Last Quarter

+1 513 255 USD

Key Figures AFMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -113 899 000 USD
Operating Margin TTM -1274.18 %
PE Ratio
Return On Assets TTM -40.19 %
PEG Ratio
Return On Equity TTM -92.55 %
Wall Street Target Price 5.67 USD
Revenue TTM 21 015 000 USD
Book Value 0.51 USD
Revenue Per Share TTM 0.14 USD
Dividend Share
Quarterly Revenue Growth YOY -87 %
Dividend Yield
Gross Profit TTM 42 869 000 USD
Earnings Share -0.86 USD
Diluted Eps TTM -0.86 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics AFMD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History AFMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation AFMD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.1985
Price Sales TTM 3.1978
Enterprise Value EBITDA 0.1402
Price Book MRQ 0.8074

Financials AFMD

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators AFMD

For 52 weeks

0.22 USD 2.15 USD
50 Day MA 0.42 USD
Shares Short Prior Month 2 162 978
200 Day MA 0.64 USD
Short Ratio 2.72
Shares Short 1 644 842
Short Percent 1.15 %